Effect of COX-2 inhibitor lumiracoxib and the TNF-α antagonist etanercept on TNBS-induced colitis in Wistar rats

Journal of Molecular Histology

Volumn 43, Issue 3, 2012, Pages 307-317

  Paiotti, Ana Paula Ribeiro ^a   Ribeiro, Daniel Araki ^a   Silva, Roseane Mendes ^a   Marchi, Patrícia ^a   Oshima, Celina Tizuko Fujiyama ^a   Neto, Ricardo Artigiani ^a   Miszputen, Sender Jankiel ^a   Franco, Marcello ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cyclooxygenase 2; Etanercept; Inflammatory bowel disease; Lumiracoxib; TNBS colitis; TNF

Indexed keywords

CYCLOOXYGENASE 2; ETANERCEPT; LUMIRACOXIB; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; CYCLOOXYGENASE 2 GENE; DOWN REGULATION; DRUG EFFECT; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR ALPHA GENE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS; COLON; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN G; INFLAMMATORY BOWEL DISEASES; MALE; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECEPTORS, TUMOR NECROSIS FACTOR; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS; RATTUS NORVEGICUS;

EID: 84865625858     PISSN: 15672379     EISSN: 15672387     Source Type: Journal    
DOI: 10.1007/s10735-012-9400-8     Document Type: Article

References (47)

1. Appleyard CB, Wallace JL (1995) Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs. Am J Physiol 269:G119-G125
2. Barbieri D (2000) Inflammatory bowel diseases. J Pediatr (Rio J) 76:S173-S180
3. Bonen DK, Cho JH (2003) The genetics of inflammatory bowel disease. Gastroenterology 124:521-536 (Pubitemid 36169267)
4. Brune K, Hinz B (2004) Selective cyclooxygenase-2 inhibitors: Similarities and differences. Scand J Rheumatol 33:1-6 (Pubitemid 38328075)
5. Colpaert S, Liu Z, De Greef B, Rutgeerts P, Ceuppens JL, Geboes K (2001a) Effects of anti-tumour necrosis factor, interleukin-10 and antibiotic therapy in the indometacin-induced bowel inflammation rat model. Aliment Pharmacol Ther 15:1827-1836 (Pubitemid 33001147)
6. Colpaert S, Liu Z, De Greef B, Rutgeerts P, Ceuppens JL, Geboes K (2001b) Effects of anti-tumour necrosis factor, interleukin-10 and antibiotic therapy in the indometacin-induced bowel inflammation rat model. Aliment Pharmacol Ther 15:1827-1836 (Pubitemid 33001147)
7. Dempke W, Rie C, Grothey A, Schmoll HJ (2001) Cyclooxygenase-2: A novel target for cancer chemotherapy? J Cancer Res Clin Oncol 127:411-417 (Pubitemid 32524357)
8. Dhar A, Brindley JM, Stark C, Citro ML, Keefer LK, Colburn NH (2003) Nitric oxide does not mediate but inhibits transformation and tumor phenotype. Mol Cancer Ther 2:1285-1293
9. Di Paola R, Mazzon E, Muia C, Crisafulli C, Terrana D, Greco S et al (2007) Effects of etanercept, a tumour necrosis factor-A antagonist, in an experimental model of periodontitis in rats. Br J Pharmacol 150:286-297 (Pubitemid 46221038)
10. E ́ lson CO, Sartor RB, Tennyson GS, Riddell RH (1995) Experimental models of inflammatory bowel disease. Gastroenterology 109:1344-1367
11. Esser R, Berry C, Du Z, Dawson J, Fox A, Fujimoto RA, Haston W, Kimble EF, Koehler J, Peppard J, Quadros E, Quintavalla J, Toscano K, Urban L, Van Duzer J, Zhang X, Zhou S, Marshall PJ (2005) Preclinical pharmacology of lumiracoxib: A novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol 144:538-550 (Pubitemid 40349461)
12. Feng L, Sun W, Xia Y, Tang WW, Chanmugam P, Soyoola E, Wilson CB, Hwang D (1993) Cloning two isoforms of rats cyclooxygenase: Differential regulation of their expression. Arch Biochem Biophys 307:361-368 (Pubitemid 24001574)
13. Fries W, Muja C, Crisafulli C, Constantino G, Longo G, Cuzzocrea S et al (2008) Infliximab and etanercept are equally effective in reducing enterocyte apoptosis in experimental colitis. Int J Med Sci 5:169-180 (Pubitemid 352000027)
14. Gibson PR (2004) Increased gut permeability in Crohn's disease: Is TNF the link? Gut 53:1724-1725 (Pubitemid 39556884)
15. Halter F, Tarnawski AS, Schmassmann A, Peskar BM (2001) Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: Controversial issues and perspectives. Gut 49:443-453 (Pubitemid 32802583)
16. Hawkey CJ, Svoboda P, Fiedorowicz-Fabrycy IF, Nasonov EL, Pikhlak EG, Cousin M, Gitton X, Hoexter G (2004) Gastroduodenal safety and tolerability of lumiracoxib compared with ibuprofen and celecoxib in patients with osteoarthritis. J Rheum 31:1804-1810 (Pubitemid 39202525)
17. Kargman S, Charlesion S, Cartwright M, Frank J, Riendeaw D, Mancini J, Evans J, O'Neill G (1996) Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 111:445-454 (Pubitemid 26256734)
18. Kivitz AJ, Nayiager S, Schimansky T, Gimona A, Thurston HJ, Hawkey C (2004) Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol Ther 19:1189-1198 (Pubitemid 38746262)
19. Lashner BA (1995) Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 24:467-474
20. Lee JK, Choi SS, Won JS, Suh WH (2003) The regulation of inducible nitric oxide synthase gene expression induced by lipopolysaccharide and tumor necrosis factor-alpha in C6 cells: Involvement of AP-1 and NfkappaB. Life Sci 73:595-609
21. Lichtenstein DR, Wolfe MM (2000) COX-2 selective NSAIDS. New and improved? J Am Med Assoc 284:1297-1299
22. Lin CC, Hsiao LD, Chien CS, Lee CW, Hsieh JT, Yang CM (2004) Tumor necrosis factor-alpha-induced cyclooxygenase-2 expression in human tracheal smooth muscle cells: Involvement of p42/ p44 and p38 mitogen-activated protein kinases and nuclear factor-kappaB. Cell Signal 16:597-607
23. Mahadevan U, Loftus EV, Tremaine WJ (2001) Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol 97:910-914
24. Mangold JB, Gu H, Rodriguez LC, Bonner J, Dickson J, Rordorf C (2004) Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab Dispos 32:566-571 (Pubitemid 38535036)
25. Mizuno H, Akamatsu T, Kasuga M (1997) Induction of cyclooxygenase-2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 112:387-397 (Pubitemid 27078825)
26. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL (1989) Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96:795-803 (Pubitemid 19057602)
27. O'Neill GP, Ford-Hutchinson AW (1993) Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 330:156-160 (Pubitemid 23265121)
28. Okayama M, Hayashi S, Aoi Y, Nishio H, Kato S, Takeuchi K (2007) Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats. Dig Dis Sci 52:2095-2103 (Pubitemid 47246503)
29. Paiotti AP, Artigiani-Neto R, Forones NM, Oshima CTF, Miszputen SJ, Franco M (2007) Immunoexpression of cyclooxygenase-1 and -2 in ulcerative colitis. Braz J Med Biol Res 40:911-918 (Pubitemid 47232875)
30. Paiotti AP, Miszputen SJ, Oshima CT, Artigiani Neto R, Ribeiro DA, Franco M (2011) Etanercept attenuates TNBS-induced experimental colitis: Role of TNF-A expression. J Mol Histol 42:443-450
31. Peran L, Camuesco D, Comalada M, Nieto A, Concha A, Diaz-Ropero MP et al (2005) Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis. World J Gastroenterol 11:5185-5192 (Pubitemid 41410337)
32. Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347:417-429 (Pubitemid 34851835)
33. Reuter BK, Asfaha S, Buret A et al (1996) Exacerbation of inflammatory associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 98:2076-2085 (Pubitemid 26376296)
34. Rordorf C, Kellett N, Mair S et al (2003) Gastroduodenal tolerability of lumiracoxib vs. placebo and naproxen: A pilot endoscopic study in healthy male subjects. Aliment Pharmacol Ther 18:533-541 (Pubitemid 37152294)
35. Shen C, Hertogh G, Bullens DMA, Assche GV, Geboes K, Rutgeerts P et al (2007a) Remission-inducing effect of anti-TNF monoclonal antibody in TNBS colitis: Mechanisms beyond neutralization? Inflamm Bowel Dis 13:308-316 (Pubitemid 46465912)
36. Shen C, Hertogh G, Bullens DMA, Assche GV, Geboes K, Rutgeerts P et al (2007b) Remission-inducing effect of anti-TNF monoclonal antibody in TNBS colitis: Mechanisms beyond neutralization? Inflamm Bowel Dis 13:308-316 (Pubitemid 46465912)
37. Shigeta J, Takahashi S, Okabe S (1998) Role of cyclooxygenase-2 in the healing of gastric ulcers in rats. J Pharmacol Exp Ther 286:1383-1390 (Pubitemid 29135552)
38. Shorter RG, Huizenga KA, Spencer RJ, Guy SK (1972) Inflammatory bowel disease. The role of lymphotoxin in the cytotoxicity of lymphocytes for colonic epithelial cells. Am J Dig Dis 17:689-696
39. Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF (1998) Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 115:297-306 (Pubitemid 28363422)
40. Somasundaram S, Rafi S, Hayllar J, Sigthorsson G, Jacob M, Price AB, Macpherson A, Mahmod T, Scott D, Wrigglesworth JM, Bjarnason I (1997) Mitochondrial damage: A possible mechanism of the ''topical'' phase of NSAID induced injury to the rat intestine. Gut 41:344-353 (Pubitemid 27428194)
41. Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van Assche G et al (2002) Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 97:2000-2004
42. Suenaert P, Bulteel V, Vermeire S, Noman M, Van Assche G, Rutgeerts P (2005a) Hyperresponsiveness of the mucosal barrier in Crohn's disease is not tumor necrosis factor-dependent. Inflamm Bowel Dis 11:667-673 (Pubitemid 40961081)
43. Suenaert P, Bulteel V, Vermeire S, Noman M, Van Assche G, Rutgeerts P (2005b) Hyperresponsiveness of the mucosal barrier in Crohn's disease is not tumor necrosis factor-dependent. Inflamm Bowel Dis 11:667-673 (Pubitemid 40961081)
44. Ukawa H, Yamakuni H, Kato S, Takeuchi K (1998) Effects of cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal anti-inflammatory drugs on gastric ulcerogenic and healing responses in experimental animals. Dig Dis Sci 43:2003-2011
45. Xiong B, Sun TJ, Hu WD, Cheng FL, Mao M, Zhou YF (2005) Expression of cyclooxygenase-2 in colorectal cancer and its clinical significance. World J Gastroenterol 11:1105-1108 (Pubitemid 40352994)
46. Zhang L, Lu YM, Dong XY (2004) Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid. Chin J Dig Dis 5:110-114 (Pubitemid 39199625)
47. Zhou YH, Yu JP, Liu YF, Teng XJ, Ming M, Lv P (2006) Effects of ginkgo biloba extract on inflammatory mediators (SOD, MDA, TNF-A, NF-jBp65, IL-6) in TNBS-induced colitis in rats. Mediators Inflamm 92642:1-9